FDA Advisory Panel To Meet On DTC Drug Advertising
This article was originally published in The Pink Sheet Daily
Panel considers DTC ads’ impact on different consumer groups, adverse event statements in broadcast ads.
You may also be interested in...
Agency faces industry pressure to define Internet ad regulations.
Drug makers need to continue investing in early-stage research to unveil the next $1 billion-plus drug, panelists at the Argyle conference agree.
Phase III data for Affymax/Takeda's anemia drug for chronic kidney failure signals potential regulatory hurdles in non-dialysis use.